Πέμπτη 10 Σεπτεμβρίου 2009

STAGE I TRIPLE NEGATIVE BREAST CANCER

Breast J. 2009 Sep-Oct;15(5):454-60. Epub 2009 Aug 4.Related Articles, LinkOut

Comment in:
T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.

Kaplan HG, Malmgren JA, Atwood M.

Swedish Cancer Institute at Swedish Medical Center, Seattle, Washington 98104, USA. hank.kaplan@swedish.org

Adjuvant treatment of T1N0 breast cancer (BC) has evolved in recent years with chemotherapy options dependent on tumor size and cellular characteristics. Our goal is to describe the difference in outcome between T1N0 triple negative (TriNeg) and estrogen/progesterone receptor positive/her2/neu-negative BC. From our institute's registry, we identified primary BC patients diagnosed from 1998 to 2005, estrogen/progesterone receptor negative (ER-/PR-)/her-2/neu negative (her2-) (TriNeg = 110) and ER+/PR+/her2- (HR+/her2- = 919). Clinical diagnosis and treatment variables were chart abstracted. Vital and disease status were updated annually. Pearson chi-squared tests were used for bivariate analysis. Hazard ratios were calculated using the Cox proportional hazards model. Average patient age was 59 years, range 23-93 years and average length of follow-up was 4.22 years. T-stage distribution for HR+/her2- patients was 9% T1a (>0.1, < or =" 0.5">0.5 cm, < or =" 1">1 cm, < or =" 2" test =" 27.77," style="border-bottom: 1px dashed rgb(0, 102, 204); background: transparent none repeat scroll 0% 0%; cursor: pointer; -moz-background-clip: border; -moz-background-origin: padding; -moz-background-inline-policy: continuous;" class="yshortcuts" id="lw_1252532318_11">hazard ratio for recurrence in the TriNeg group was 6.57 (95% CI = 2.34, 18.49) adjusted for age, tumor size, and adjuvant chemotherapy. Triple negative T1N0 patients have greater recurrence risk in spite of more aggressive therapy by both number treated and adjuvant chemotherapy type even in a low-risk category. New treatment modalities specific for triple negative disease are urgently needed.

Δεν υπάρχουν σχόλια: